Global Circular RNA Drugs Supply, Demand and Key Producers, 2026-2032
The global Circular RNA Drugs market size is expected to reach $ 503 million by 2032, rising at a market growth of 38.6% CAGR during the forecast period (2026-2032).
Circular RNA drugs are an emerging class of RNA therapeutics that use engineered circular RNA as the core active ingredient or expression vector. These products are generally developed through sequence design, in vitro transcription, circularization, purification, delivery formulation development, and GMP scale-up manufacturing to form drug candidates. Key application areas include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic disease repair, and rare disease treatment. Upstream materials mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, analytical testing reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative pharmaceutical companies, RNA drug platform companies, vaccine companies, CRO/CDMO providers, hospital clinical research centers, and collaborative projects with large pharmaceutical companies.
The current circular RNA drugs market remains at an early stage of clinical translation, with industry activity mainly focused on platform validation, candidate selection, circularization process optimization, delivery system development, and clinical safety evaluation. Compared with traditional small-molecule drugs, antibody drugs, and some commercialized mRNA vaccines, circular RNA drugs have not yet established a large-scale end-market sales model. Company value is still mainly reflected in technology platforms, pipeline progress, patent coverage, collaborative R&D capability, and CMC scale-up capability. At this stage, the number of core global players remains limited, with major participants concentrated in the United States and China, while European companies are more active in virus-vector-based circular RNA expression and gene therapy-related directions. Overall, the industry remains an emerging field with high R&D intensity, high technical barriers, and significant uncertainty.
Future development will be centered on the transition from platform concept to clinical validation. Early-stage companies have mainly emphasized the theoretical advantages of circular RNA in stability, expression duration, and programmability, while the next phase of competition will focus more on safety, efficacy, immunogenicity control, and dose-response performance in human studies. As more candidates enter clinical development, the industry is expected to gradually form application clusters around therapeutic vaccines, in vivo cell therapy, local tissue repair, protein-expression therapy, and rare disease treatment. At the same time, circularization efficiency, RNA purity, impurity control, tissue selectivity of LNP or other delivery systems, and consistency in GMP scale-up manufacturing will become key factors determining whether a company can evolve from a research platform into a drug developer.
Market growth is mainly driven by the evolution of RNA drug technologies, unmet clinical needs, capital support, large-pharma collaboration, accumulating regulatory experience, and progress in biomanufacturing processes. Compared with linear mRNA, circular RNA may offer a longer expression window and potentially lower dosing frequency, giving it differentiated value in scenarios that require sustained therapeutic protein expression or localized release of functional factors. Cancer immunotherapy, autoimmune diseases, ischemic cardiovascular diseases, rare diseases, and in vivo CAR-T are likely to become important early validation areas. The growing interest of large pharmaceutical companies in next-generation RNA platforms may also support more licensing deals, acquisitions, and co-development programs, providing small and mid-sized platform companies with funding, clinical development resources, and global registration capabilities.
The main barriers lie in the still-evolving technical maturity, clinical validation, and industrialization pathway. Although circular RNA has potential advantages in molecular stability, its in vivo translation efficiency, delivery efficiency, immune response, long-term safety, and controllability of expression across different tissues still require systematic validation. On the manufacturing side, companies also face challenges related to circularization yield, removal of linear RNA and by-products, batch-to-batch consistency, quality standard development, and cost control. Regulatory review pathways for circular RNA drugs are still being shaped, and differences among technical routes may affect clinical filing and quality-control requirements. Therefore, while the industry has strong long-term growth potential, it is likely to remain R&D-driven in the near term, with significant project differentiation and a high attrition rate.
This report studies the global Circular RNA Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Circular RNA Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Circular RNA Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Circular RNA Drugs total market, 2021-2032, (USD Million)
Global Circular RNA Drugs total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Circular RNA Drugs total market, key domestic companies, and share, (USD Million)
Global Circular RNA Drugs revenue by player, revenue and market share 2021-2026, (USD Million)
Global Circular RNA Drugs total market by Type, CAGR, 2021-2032, (USD Million)
Global Circular RNA Drugs total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Circular RNA Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Orna Therapeutics, RiboX Therapeutics, Sail Biomedicines, Chimerna Therapeutics, Torque Bio, Circurna, Shanghai CirCode Biomed, Therorna, Circio Holding, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Circular RNA Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Circular RNA Drugs Market, By Region:
1. How big is the global Circular RNA Drugs market?
2. What is the demand of the global Circular RNA Drugs market?
3. What is the year over year growth of the global Circular RNA Drugs market?
4. What is the total value of the global Circular RNA Drugs market?
5. Who are the Major Players in the global Circular RNA Drugs market?
6. What are the growth factors driving the market demand?
Circular RNA drugs are an emerging class of RNA therapeutics that use engineered circular RNA as the core active ingredient or expression vector. These products are generally developed through sequence design, in vitro transcription, circularization, purification, delivery formulation development, and GMP scale-up manufacturing to form drug candidates. Key application areas include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic disease repair, and rare disease treatment. Upstream materials mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, analytical testing reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative pharmaceutical companies, RNA drug platform companies, vaccine companies, CRO/CDMO providers, hospital clinical research centers, and collaborative projects with large pharmaceutical companies.
The current circular RNA drugs market remains at an early stage of clinical translation, with industry activity mainly focused on platform validation, candidate selection, circularization process optimization, delivery system development, and clinical safety evaluation. Compared with traditional small-molecule drugs, antibody drugs, and some commercialized mRNA vaccines, circular RNA drugs have not yet established a large-scale end-market sales model. Company value is still mainly reflected in technology platforms, pipeline progress, patent coverage, collaborative R&D capability, and CMC scale-up capability. At this stage, the number of core global players remains limited, with major participants concentrated in the United States and China, while European companies are more active in virus-vector-based circular RNA expression and gene therapy-related directions. Overall, the industry remains an emerging field with high R&D intensity, high technical barriers, and significant uncertainty.
Future development will be centered on the transition from platform concept to clinical validation. Early-stage companies have mainly emphasized the theoretical advantages of circular RNA in stability, expression duration, and programmability, while the next phase of competition will focus more on safety, efficacy, immunogenicity control, and dose-response performance in human studies. As more candidates enter clinical development, the industry is expected to gradually form application clusters around therapeutic vaccines, in vivo cell therapy, local tissue repair, protein-expression therapy, and rare disease treatment. At the same time, circularization efficiency, RNA purity, impurity control, tissue selectivity of LNP or other delivery systems, and consistency in GMP scale-up manufacturing will become key factors determining whether a company can evolve from a research platform into a drug developer.
Market growth is mainly driven by the evolution of RNA drug technologies, unmet clinical needs, capital support, large-pharma collaboration, accumulating regulatory experience, and progress in biomanufacturing processes. Compared with linear mRNA, circular RNA may offer a longer expression window and potentially lower dosing frequency, giving it differentiated value in scenarios that require sustained therapeutic protein expression or localized release of functional factors. Cancer immunotherapy, autoimmune diseases, ischemic cardiovascular diseases, rare diseases, and in vivo CAR-T are likely to become important early validation areas. The growing interest of large pharmaceutical companies in next-generation RNA platforms may also support more licensing deals, acquisitions, and co-development programs, providing small and mid-sized platform companies with funding, clinical development resources, and global registration capabilities.
The main barriers lie in the still-evolving technical maturity, clinical validation, and industrialization pathway. Although circular RNA has potential advantages in molecular stability, its in vivo translation efficiency, delivery efficiency, immune response, long-term safety, and controllability of expression across different tissues still require systematic validation. On the manufacturing side, companies also face challenges related to circularization yield, removal of linear RNA and by-products, batch-to-batch consistency, quality standard development, and cost control. Regulatory review pathways for circular RNA drugs are still being shaped, and differences among technical routes may affect clinical filing and quality-control requirements. Therefore, while the industry has strong long-term growth potential, it is likely to remain R&D-driven in the near term, with significant project differentiation and a high attrition rate.
This report studies the global Circular RNA Drugs demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Circular RNA Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Circular RNA Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Circular RNA Drugs total market, 2021-2032, (USD Million)
Global Circular RNA Drugs total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Circular RNA Drugs total market, key domestic companies, and share, (USD Million)
Global Circular RNA Drugs revenue by player, revenue and market share 2021-2026, (USD Million)
Global Circular RNA Drugs total market by Type, CAGR, 2021-2032, (USD Million)
Global Circular RNA Drugs total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Circular RNA Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Orna Therapeutics, RiboX Therapeutics, Sail Biomedicines, Chimerna Therapeutics, Torque Bio, Circurna, Shanghai CirCode Biomed, Therorna, Circio Holding, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Circular RNA Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Circular RNA Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Protein Expression Therapeutics
- Therapeutic Vaccines
- Other
- Lipid Nanoparticle Delivery
- Local Direct Delivery
- Other
- Intravenous Administration
- Local Injection
- Other
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Other
- Orna Therapeutics
- RiboX Therapeutics
- Sail Biomedicines
- Chimerna Therapeutics
- Torque Bio
- Circurna
- Shanghai CirCode Biomed
- Therorna
- Circio Holding
1. How big is the global Circular RNA Drugs market?
2. What is the demand of the global Circular RNA Drugs market?
3. What is the year over year growth of the global Circular RNA Drugs market?
4. What is the total value of the global Circular RNA Drugs market?
5. Who are the Major Players in the global Circular RNA Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Circular RNA Drugs Introduction
1.2 World Circular RNA Drugs Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Circular RNA Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Circular RNA Drugs Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.3 China Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.4 Europe Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.5 Japan Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.6 South Korea Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.7 ASEAN Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.8 India Based Company Circular RNA Drugs Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Circular RNA Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Circular RNA Drugs Consumption Value (2021-2032)
2.2 World Circular RNA Drugs Consumption Value by Region
2.2.1 World Circular RNA Drugs Consumption Value by Region (2021-2026)
2.2.2 World Circular RNA Drugs Consumption Value Forecast by Region (2027-2032)
2.3 United States Circular RNA Drugs Consumption Value (2021-2032)
2.4 China Circular RNA Drugs Consumption Value (2021-2032)
2.5 Europe Circular RNA Drugs Consumption Value (2021-2032)
2.6 Japan Circular RNA Drugs Consumption Value (2021-2032)
2.7 South Korea Circular RNA Drugs Consumption Value (2021-2032)
2.8 ASEAN Circular RNA Drugs Consumption Value (2021-2032)
2.9 India Circular RNA Drugs Consumption Value (2021-2032)
3 WORLD CIRCULAR RNA DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Circular RNA Drugs Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Circular RNA Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Circular RNA Drugs in 2025
3.2.3 Global Concentration Ratios (CR8) for Circular RNA Drugs in 2025
3.3 Circular RNA Drugs Company Evaluation Quadrant
3.4 Circular RNA Drugs Market: Overall Company Footprint Analysis
3.4.1 Circular RNA Drugs Market: Region Footprint
3.4.2 Circular RNA Drugs Market: Company Product Type Footprint
3.4.3 Circular RNA Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Circular RNA Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Circular RNA Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Circular RNA Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Circular RNA Drugs Consumption Value Comparison
4.2.1 United States VS China: Circular RNA Drugs Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Circular RNA Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Circular RNA Drugs Companies and Market Share, 2021-2026
4.3.1 United States Based Circular RNA Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Circular RNA Drugs Revenue, (2021-2026)
4.4 China Based Companies Circular RNA Drugs Revenue and Market Share, 2021-2026
4.4.1 China Based Circular RNA Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Circular RNA Drugs Revenue, (2021-2026)
4.5 Rest of World Based Circular RNA Drugs Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Circular RNA Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Circular RNA Drugs Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Circular RNA Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Protein Expression Therapeutics
5.2.2 Therapeutic Vaccines
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Circular RNA Drugs Market Size by Type (2021-2026)
5.3.2 World Circular RNA Drugs Market Size by Type (2027-2032)
5.3.3 World Circular RNA Drugs Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY DELIVERY TECHNOLOGY
6.1 World Circular RNA Drugs Market Size Overview by Delivery Technology: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Delivery Technology
6.2.1 Lipid Nanoparticle Delivery
6.2.2 Local Direct Delivery
6.2.3 Other
6.3 Market Segment by Delivery Technology
6.3.1 World Circular RNA Drugs Market Size by Delivery Technology (2021-2026)
6.3.2 World Circular RNA Drugs Market Size by Delivery Technology (2027-2032)
6.3.3 World Circular RNA Drugs Market Size Market Share by Delivery Technology (2027-2032)
7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 World Circular RNA Drugs Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Intravenous Administration
7.2.2 Local Injection
7.2.3 Other
7.3 Market Segment by Route of Administration
7.3.1 World Circular RNA Drugs Market Size by Route of Administration (2021-2026)
7.3.2 World Circular RNA Drugs Market Size by Route of Administration (2027-2032)
7.3.3 World Circular RNA Drugs Market Size Market Share by Route of Administration (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Circular RNA Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical and Biotechnology Companies
8.2.2 Research Institutes
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Circular RNA Drugs Market Size by Application (2021-2026)
8.3.2 World Circular RNA Drugs Market Size by Application (2027-2032)
8.3.3 World Circular RNA Drugs Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Orna Therapeutics
9.1.1 Orna Therapeutics Details
9.1.2 Orna Therapeutics Major Business
9.1.3 Orna Therapeutics Circular RNA Drugs Product and Services
9.1.4 Orna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Orna Therapeutics Recent Developments/Updates
9.1.6 Orna Therapeutics Competitive Strengths & Weaknesses
9.2 RiboX Therapeutics
9.2.1 RiboX Therapeutics Details
9.2.2 RiboX Therapeutics Major Business
9.2.3 RiboX Therapeutics Circular RNA Drugs Product and Services
9.2.4 RiboX Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 RiboX Therapeutics Recent Developments/Updates
9.2.6 RiboX Therapeutics Competitive Strengths & Weaknesses
9.3 Sail Biomedicines
9.3.1 Sail Biomedicines Details
9.3.2 Sail Biomedicines Major Business
9.3.3 Sail Biomedicines Circular RNA Drugs Product and Services
9.3.4 Sail Biomedicines Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Sail Biomedicines Recent Developments/Updates
9.3.6 Sail Biomedicines Competitive Strengths & Weaknesses
9.4 Chimerna Therapeutics
9.4.1 Chimerna Therapeutics Details
9.4.2 Chimerna Therapeutics Major Business
9.4.3 Chimerna Therapeutics Circular RNA Drugs Product and Services
9.4.4 Chimerna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Chimerna Therapeutics Recent Developments/Updates
9.4.6 Chimerna Therapeutics Competitive Strengths & Weaknesses
9.5 Torque Bio
9.5.1 Torque Bio Details
9.5.2 Torque Bio Major Business
9.5.3 Torque Bio Circular RNA Drugs Product and Services
9.5.4 Torque Bio Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Torque Bio Recent Developments/Updates
9.5.6 Torque Bio Competitive Strengths & Weaknesses
9.6 Circurna
9.6.1 Circurna Details
9.6.2 Circurna Major Business
9.6.3 Circurna Circular RNA Drugs Product and Services
9.6.4 Circurna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Circurna Recent Developments/Updates
9.6.6 Circurna Competitive Strengths & Weaknesses
9.7 Shanghai CirCode Biomed
9.7.1 Shanghai CirCode Biomed Details
9.7.2 Shanghai CirCode Biomed Major Business
9.7.3 Shanghai CirCode Biomed Circular RNA Drugs Product and Services
9.7.4 Shanghai CirCode Biomed Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Shanghai CirCode Biomed Recent Developments/Updates
9.7.6 Shanghai CirCode Biomed Competitive Strengths & Weaknesses
9.8 Therorna
9.8.1 Therorna Details
9.8.2 Therorna Major Business
9.8.3 Therorna Circular RNA Drugs Product and Services
9.8.4 Therorna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Therorna Recent Developments/Updates
9.8.6 Therorna Competitive Strengths & Weaknesses
9.9 Circio Holding
9.9.1 Circio Holding Details
9.9.2 Circio Holding Major Business
9.9.3 Circio Holding Circular RNA Drugs Product and Services
9.9.4 Circio Holding Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Circio Holding Recent Developments/Updates
9.9.6 Circio Holding Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Circular RNA Drugs Industry Chain
10.2 Circular RNA Drugs Upstream Analysis
10.3 Circular RNA Drugs Midstream Analysis
10.4 Circular RNA Drugs Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Circular RNA Drugs Introduction
1.2 World Circular RNA Drugs Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Circular RNA Drugs Total Market by Region (by Headquarter Location)
1.3.1 World Circular RNA Drugs Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.3 China Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.4 Europe Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.5 Japan Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.6 South Korea Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.7 ASEAN Based Company Circular RNA Drugs Revenue (2021-2032)
1.3.8 India Based Company Circular RNA Drugs Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Circular RNA Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Circular RNA Drugs Consumption Value (2021-2032)
2.2 World Circular RNA Drugs Consumption Value by Region
2.2.1 World Circular RNA Drugs Consumption Value by Region (2021-2026)
2.2.2 World Circular RNA Drugs Consumption Value Forecast by Region (2027-2032)
2.3 United States Circular RNA Drugs Consumption Value (2021-2032)
2.4 China Circular RNA Drugs Consumption Value (2021-2032)
2.5 Europe Circular RNA Drugs Consumption Value (2021-2032)
2.6 Japan Circular RNA Drugs Consumption Value (2021-2032)
2.7 South Korea Circular RNA Drugs Consumption Value (2021-2032)
2.8 ASEAN Circular RNA Drugs Consumption Value (2021-2032)
2.9 India Circular RNA Drugs Consumption Value (2021-2032)
3 WORLD CIRCULAR RNA DRUGS COMPANIES COMPETITIVE ANALYSIS
3.1 World Circular RNA Drugs Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Circular RNA Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Circular RNA Drugs in 2025
3.2.3 Global Concentration Ratios (CR8) for Circular RNA Drugs in 2025
3.3 Circular RNA Drugs Company Evaluation Quadrant
3.4 Circular RNA Drugs Market: Overall Company Footprint Analysis
3.4.1 Circular RNA Drugs Market: Region Footprint
3.4.2 Circular RNA Drugs Market: Company Product Type Footprint
3.4.3 Circular RNA Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Circular RNA Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Circular RNA Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Circular RNA Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Circular RNA Drugs Consumption Value Comparison
4.2.1 United States VS China: Circular RNA Drugs Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Circular RNA Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Circular RNA Drugs Companies and Market Share, 2021-2026
4.3.1 United States Based Circular RNA Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Circular RNA Drugs Revenue, (2021-2026)
4.4 China Based Companies Circular RNA Drugs Revenue and Market Share, 2021-2026
4.4.1 China Based Circular RNA Drugs Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Circular RNA Drugs Revenue, (2021-2026)
4.5 Rest of World Based Circular RNA Drugs Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Circular RNA Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Circular RNA Drugs Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Circular RNA Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Protein Expression Therapeutics
5.2.2 Therapeutic Vaccines
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Circular RNA Drugs Market Size by Type (2021-2026)
5.3.2 World Circular RNA Drugs Market Size by Type (2027-2032)
5.3.3 World Circular RNA Drugs Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY DELIVERY TECHNOLOGY
6.1 World Circular RNA Drugs Market Size Overview by Delivery Technology: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Delivery Technology
6.2.1 Lipid Nanoparticle Delivery
6.2.2 Local Direct Delivery
6.2.3 Other
6.3 Market Segment by Delivery Technology
6.3.1 World Circular RNA Drugs Market Size by Delivery Technology (2021-2026)
6.3.2 World Circular RNA Drugs Market Size by Delivery Technology (2027-2032)
6.3.3 World Circular RNA Drugs Market Size Market Share by Delivery Technology (2027-2032)
7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 World Circular RNA Drugs Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Intravenous Administration
7.2.2 Local Injection
7.2.3 Other
7.3 Market Segment by Route of Administration
7.3.1 World Circular RNA Drugs Market Size by Route of Administration (2021-2026)
7.3.2 World Circular RNA Drugs Market Size by Route of Administration (2027-2032)
7.3.3 World Circular RNA Drugs Market Size Market Share by Route of Administration (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Circular RNA Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical and Biotechnology Companies
8.2.2 Research Institutes
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Circular RNA Drugs Market Size by Application (2021-2026)
8.3.2 World Circular RNA Drugs Market Size by Application (2027-2032)
8.3.3 World Circular RNA Drugs Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Orna Therapeutics
9.1.1 Orna Therapeutics Details
9.1.2 Orna Therapeutics Major Business
9.1.3 Orna Therapeutics Circular RNA Drugs Product and Services
9.1.4 Orna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Orna Therapeutics Recent Developments/Updates
9.1.6 Orna Therapeutics Competitive Strengths & Weaknesses
9.2 RiboX Therapeutics
9.2.1 RiboX Therapeutics Details
9.2.2 RiboX Therapeutics Major Business
9.2.3 RiboX Therapeutics Circular RNA Drugs Product and Services
9.2.4 RiboX Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 RiboX Therapeutics Recent Developments/Updates
9.2.6 RiboX Therapeutics Competitive Strengths & Weaknesses
9.3 Sail Biomedicines
9.3.1 Sail Biomedicines Details
9.3.2 Sail Biomedicines Major Business
9.3.3 Sail Biomedicines Circular RNA Drugs Product and Services
9.3.4 Sail Biomedicines Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Sail Biomedicines Recent Developments/Updates
9.3.6 Sail Biomedicines Competitive Strengths & Weaknesses
9.4 Chimerna Therapeutics
9.4.1 Chimerna Therapeutics Details
9.4.2 Chimerna Therapeutics Major Business
9.4.3 Chimerna Therapeutics Circular RNA Drugs Product and Services
9.4.4 Chimerna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Chimerna Therapeutics Recent Developments/Updates
9.4.6 Chimerna Therapeutics Competitive Strengths & Weaknesses
9.5 Torque Bio
9.5.1 Torque Bio Details
9.5.2 Torque Bio Major Business
9.5.3 Torque Bio Circular RNA Drugs Product and Services
9.5.4 Torque Bio Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Torque Bio Recent Developments/Updates
9.5.6 Torque Bio Competitive Strengths & Weaknesses
9.6 Circurna
9.6.1 Circurna Details
9.6.2 Circurna Major Business
9.6.3 Circurna Circular RNA Drugs Product and Services
9.6.4 Circurna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Circurna Recent Developments/Updates
9.6.6 Circurna Competitive Strengths & Weaknesses
9.7 Shanghai CirCode Biomed
9.7.1 Shanghai CirCode Biomed Details
9.7.2 Shanghai CirCode Biomed Major Business
9.7.3 Shanghai CirCode Biomed Circular RNA Drugs Product and Services
9.7.4 Shanghai CirCode Biomed Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Shanghai CirCode Biomed Recent Developments/Updates
9.7.6 Shanghai CirCode Biomed Competitive Strengths & Weaknesses
9.8 Therorna
9.8.1 Therorna Details
9.8.2 Therorna Major Business
9.8.3 Therorna Circular RNA Drugs Product and Services
9.8.4 Therorna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Therorna Recent Developments/Updates
9.8.6 Therorna Competitive Strengths & Weaknesses
9.9 Circio Holding
9.9.1 Circio Holding Details
9.9.2 Circio Holding Major Business
9.9.3 Circio Holding Circular RNA Drugs Product and Services
9.9.4 Circio Holding Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Circio Holding Recent Developments/Updates
9.9.6 Circio Holding Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Circular RNA Drugs Industry Chain
10.2 Circular RNA Drugs Upstream Analysis
10.3 Circular RNA Drugs Midstream Analysis
10.4 Circular RNA Drugs Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Circular RNA Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Circular RNA Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Circular RNA Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Circular RNA Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Circular RNA Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Circular RNA Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Circular RNA Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Circular RNA Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Circular RNA Drugs Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Circular RNA Drugs Players in 2025
Table 12. World Circular RNA Drugs Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Circular RNA Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Circular RNA Drugs Players
Table 15. Circular RNA Drugs Market: Company Product Type Footprint
Table 16. Circular RNA Drugs Market: Company Product Application Footprint
Table 17. Circular RNA Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Circular RNA Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Circular RNA Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Circular RNA Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Circular RNA Drugs Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Circular RNA Drugs Revenue Market Share (2021-2026)
Table 23. China Based Circular RNA Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Circular RNA Drugs Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Circular RNA Drugs Revenue Market Share (2021-2026)
Table 26. Rest of World Based Circular RNA Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Circular RNA Drugs Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Circular RNA Drugs Revenue Market Share (2021-2026)
Table 29. World Circular RNA Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Circular RNA Drugs Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Circular RNA Drugs Market Size by Type (2027-2032) & (USD Million)
Table 32. World Circular RNA Drugs Market Size by Delivery Technology, (USD Million), 2021 & 2025 & 2032
Table 33. World Circular RNA Drugs Market Size Value by Delivery Technology (2021-2026) & (USD Million)
Table 34. World Circular RNA Drugs Market Size by Delivery Technology (2027-2032) & (USD Million)
Table 35. World Circular RNA Drugs Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 36. World Circular RNA Drugs Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 37. World Circular RNA Drugs Market Size by Route of Administration (2027-2032) & (USD Million)
Table 38. World Circular RNA Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Circular RNA Drugs Market Size by Application (2021-2026) & (USD Million)
Table 40. World Circular RNA Drugs Market Size by Application (2027-2032) & (USD Million)
Table 41. Orna Therapeutics Basic Information, Manufacturing Base and Competitors
Table 42. Orna Therapeutics Major Business
Table 43. Orna Therapeutics Circular RNA Drugs Product and Services
Table 44. Orna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Orna Therapeutics Recent Developments/Updates
Table 46. Orna Therapeutics Competitive Strengths & Weaknesses
Table 47. RiboX Therapeutics Basic Information, Manufacturing Base and Competitors
Table 48. RiboX Therapeutics Major Business
Table 49. RiboX Therapeutics Circular RNA Drugs Product and Services
Table 50. RiboX Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. RiboX Therapeutics Recent Developments/Updates
Table 52. RiboX Therapeutics Competitive Strengths & Weaknesses
Table 53. Sail Biomedicines Basic Information, Manufacturing Base and Competitors
Table 54. Sail Biomedicines Major Business
Table 55. Sail Biomedicines Circular RNA Drugs Product and Services
Table 56. Sail Biomedicines Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Sail Biomedicines Recent Developments/Updates
Table 58. Sail Biomedicines Competitive Strengths & Weaknesses
Table 59. Chimerna Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Chimerna Therapeutics Major Business
Table 61. Chimerna Therapeutics Circular RNA Drugs Product and Services
Table 62. Chimerna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Chimerna Therapeutics Recent Developments/Updates
Table 64. Chimerna Therapeutics Competitive Strengths & Weaknesses
Table 65. Torque Bio Basic Information, Manufacturing Base and Competitors
Table 66. Torque Bio Major Business
Table 67. Torque Bio Circular RNA Drugs Product and Services
Table 68. Torque Bio Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Torque Bio Recent Developments/Updates
Table 70. Torque Bio Competitive Strengths & Weaknesses
Table 71. Circurna Basic Information, Manufacturing Base and Competitors
Table 72. Circurna Major Business
Table 73. Circurna Circular RNA Drugs Product and Services
Table 74. Circurna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Circurna Recent Developments/Updates
Table 76. Circurna Competitive Strengths & Weaknesses
Table 77. Shanghai CirCode Biomed Basic Information, Manufacturing Base and Competitors
Table 78. Shanghai CirCode Biomed Major Business
Table 79. Shanghai CirCode Biomed Circular RNA Drugs Product and Services
Table 80. Shanghai CirCode Biomed Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Shanghai CirCode Biomed Recent Developments/Updates
Table 82. Shanghai CirCode Biomed Competitive Strengths & Weaknesses
Table 83. Therorna Basic Information, Manufacturing Base and Competitors
Table 84. Therorna Major Business
Table 85. Therorna Circular RNA Drugs Product and Services
Table 86. Therorna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Therorna Recent Developments/Updates
Table 88. Therorna Competitive Strengths & Weaknesses
Table 89. Circio Holding Basic Information, Manufacturing Base and Competitors
Table 90. Circio Holding Major Business
Table 91. Circio Holding Circular RNA Drugs Product and Services
Table 92. Circio Holding Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Circio Holding Recent Developments/Updates
Table 94. Circio Holding Competitive Strengths & Weaknesses
Table 95. Global Key Players of Circular RNA Drugs Upstream (Raw Materials)
Table 96. Global Circular RNA Drugs Typical Customers
Table 1. World Circular RNA Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Circular RNA Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Circular RNA Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Circular RNA Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Circular RNA Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Circular RNA Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Circular RNA Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Circular RNA Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Circular RNA Drugs Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Circular RNA Drugs Players in 2025
Table 12. World Circular RNA Drugs Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Circular RNA Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Circular RNA Drugs Players
Table 15. Circular RNA Drugs Market: Company Product Type Footprint
Table 16. Circular RNA Drugs Market: Company Product Application Footprint
Table 17. Circular RNA Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Circular RNA Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Circular RNA Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Circular RNA Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Circular RNA Drugs Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Circular RNA Drugs Revenue Market Share (2021-2026)
Table 23. China Based Circular RNA Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Circular RNA Drugs Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Circular RNA Drugs Revenue Market Share (2021-2026)
Table 26. Rest of World Based Circular RNA Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Circular RNA Drugs Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Circular RNA Drugs Revenue Market Share (2021-2026)
Table 29. World Circular RNA Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Circular RNA Drugs Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Circular RNA Drugs Market Size by Type (2027-2032) & (USD Million)
Table 32. World Circular RNA Drugs Market Size by Delivery Technology, (USD Million), 2021 & 2025 & 2032
Table 33. World Circular RNA Drugs Market Size Value by Delivery Technology (2021-2026) & (USD Million)
Table 34. World Circular RNA Drugs Market Size by Delivery Technology (2027-2032) & (USD Million)
Table 35. World Circular RNA Drugs Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 36. World Circular RNA Drugs Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 37. World Circular RNA Drugs Market Size by Route of Administration (2027-2032) & (USD Million)
Table 38. World Circular RNA Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Circular RNA Drugs Market Size by Application (2021-2026) & (USD Million)
Table 40. World Circular RNA Drugs Market Size by Application (2027-2032) & (USD Million)
Table 41. Orna Therapeutics Basic Information, Manufacturing Base and Competitors
Table 42. Orna Therapeutics Major Business
Table 43. Orna Therapeutics Circular RNA Drugs Product and Services
Table 44. Orna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Orna Therapeutics Recent Developments/Updates
Table 46. Orna Therapeutics Competitive Strengths & Weaknesses
Table 47. RiboX Therapeutics Basic Information, Manufacturing Base and Competitors
Table 48. RiboX Therapeutics Major Business
Table 49. RiboX Therapeutics Circular RNA Drugs Product and Services
Table 50. RiboX Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. RiboX Therapeutics Recent Developments/Updates
Table 52. RiboX Therapeutics Competitive Strengths & Weaknesses
Table 53. Sail Biomedicines Basic Information, Manufacturing Base and Competitors
Table 54. Sail Biomedicines Major Business
Table 55. Sail Biomedicines Circular RNA Drugs Product and Services
Table 56. Sail Biomedicines Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Sail Biomedicines Recent Developments/Updates
Table 58. Sail Biomedicines Competitive Strengths & Weaknesses
Table 59. Chimerna Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Chimerna Therapeutics Major Business
Table 61. Chimerna Therapeutics Circular RNA Drugs Product and Services
Table 62. Chimerna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Chimerna Therapeutics Recent Developments/Updates
Table 64. Chimerna Therapeutics Competitive Strengths & Weaknesses
Table 65. Torque Bio Basic Information, Manufacturing Base and Competitors
Table 66. Torque Bio Major Business
Table 67. Torque Bio Circular RNA Drugs Product and Services
Table 68. Torque Bio Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Torque Bio Recent Developments/Updates
Table 70. Torque Bio Competitive Strengths & Weaknesses
Table 71. Circurna Basic Information, Manufacturing Base and Competitors
Table 72. Circurna Major Business
Table 73. Circurna Circular RNA Drugs Product and Services
Table 74. Circurna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Circurna Recent Developments/Updates
Table 76. Circurna Competitive Strengths & Weaknesses
Table 77. Shanghai CirCode Biomed Basic Information, Manufacturing Base and Competitors
Table 78. Shanghai CirCode Biomed Major Business
Table 79. Shanghai CirCode Biomed Circular RNA Drugs Product and Services
Table 80. Shanghai CirCode Biomed Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Shanghai CirCode Biomed Recent Developments/Updates
Table 82. Shanghai CirCode Biomed Competitive Strengths & Weaknesses
Table 83. Therorna Basic Information, Manufacturing Base and Competitors
Table 84. Therorna Major Business
Table 85. Therorna Circular RNA Drugs Product and Services
Table 86. Therorna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Therorna Recent Developments/Updates
Table 88. Therorna Competitive Strengths & Weaknesses
Table 89. Circio Holding Basic Information, Manufacturing Base and Competitors
Table 90. Circio Holding Major Business
Table 91. Circio Holding Circular RNA Drugs Product and Services
Table 92. Circio Holding Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Circio Holding Recent Developments/Updates
Table 94. Circio Holding Competitive Strengths & Weaknesses
Table 95. Global Key Players of Circular RNA Drugs Upstream (Raw Materials)
Table 96. Global Circular RNA Drugs Typical Customers
LIST OF FIGURES
Figure 1. Circular RNA Drugs Picture
Figure 2. World Circular RNA Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Circular RNA Drugs Total Revenue (2021-2032) & (USD Million)
Figure 4. World Circular RNA Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Circular RNA Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 13. Circular RNA Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. World Circular RNA Drugs Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. China Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 23. India Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Circular RNA Drugs by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Circular RNA Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Circular RNA Drugs Markets in 2025
Figure 27. United States VS China: Circular RNA Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Circular RNA Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Circular RNA Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Circular RNA Drugs Market Size Market Share by Type in 2025
Figure 31. Protein Expression Therapeutics
Figure 32. Therapeutic Vaccines
Figure 33. Other
Figure 34. World Circular RNA Drugs Market Size Market Share by Type (2021-2032)
Figure 35. World Circular RNA Drugs Market Size by Delivery Technology, (USD Million), 2021 & 2025 & 2032
Figure 36. World Circular RNA Drugs Market Size Market Share by Delivery Technology in 2025
Figure 37. Lipid Nanoparticle Delivery
Figure 38. Local Direct Delivery
Figure 39. Other
Figure 40. World Circular RNA Drugs Market Size Market Share by Delivery Technology (2021-2032)
Figure 41. World Circular RNA Drugs Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 42. World Circular RNA Drugs Market Size Market Share by Route of Administration in 2025
Figure 43. Intravenous Administration
Figure 44. Local Injection
Figure 45. Other
Figure 46. World Circular RNA Drugs Market Size Market Share by Route of Administration (2021-2032)
Figure 47. World Circular RNA Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Circular RNA Drugs Market Size Market Share by Application in 2025
Figure 49. Pharmaceutical and Biotechnology Companies
Figure 50. Research Institutes
Figure 51. Other
Figure 52. World Circular RNA Drugs Market Size Market Share by Application (2021-2032)
Figure 53. Circular RNA Drugs Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source
Figure 1. Circular RNA Drugs Picture
Figure 2. World Circular RNA Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Circular RNA Drugs Total Revenue (2021-2032) & (USD Million)
Figure 4. World Circular RNA Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Circular RNA Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Circular RNA Drugs Revenue (2021-2032) & (USD Million)
Figure 13. Circular RNA Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. World Circular RNA Drugs Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. China Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 23. India Circular RNA Drugs Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Circular RNA Drugs by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Circular RNA Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Circular RNA Drugs Markets in 2025
Figure 27. United States VS China: Circular RNA Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Circular RNA Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Circular RNA Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Circular RNA Drugs Market Size Market Share by Type in 2025
Figure 31. Protein Expression Therapeutics
Figure 32. Therapeutic Vaccines
Figure 33. Other
Figure 34. World Circular RNA Drugs Market Size Market Share by Type (2021-2032)
Figure 35. World Circular RNA Drugs Market Size by Delivery Technology, (USD Million), 2021 & 2025 & 2032
Figure 36. World Circular RNA Drugs Market Size Market Share by Delivery Technology in 2025
Figure 37. Lipid Nanoparticle Delivery
Figure 38. Local Direct Delivery
Figure 39. Other
Figure 40. World Circular RNA Drugs Market Size Market Share by Delivery Technology (2021-2032)
Figure 41. World Circular RNA Drugs Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 42. World Circular RNA Drugs Market Size Market Share by Route of Administration in 2025
Figure 43. Intravenous Administration
Figure 44. Local Injection
Figure 45. Other
Figure 46. World Circular RNA Drugs Market Size Market Share by Route of Administration (2021-2032)
Figure 47. World Circular RNA Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Circular RNA Drugs Market Size Market Share by Application in 2025
Figure 49. Pharmaceutical and Biotechnology Companies
Figure 50. Research Institutes
Figure 51. Other
Figure 52. World Circular RNA Drugs Market Size Market Share by Application (2021-2032)
Figure 53. Circular RNA Drugs Industrial Chain
Figure 54. Methodology
Figure 55. Research Process and Data Source
